Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Williams-Sonoma, Inc. — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.4 (market cap $7.35B), while Williams-Sonoma, Inc. trades at $244.66 (market cap $28.26B). The key difference: Williams-Sonoma, Inc. is far larger — about 3.8× Spyre Therapeutics Inc. Common Stock's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Williams-Sonoma, Inc. for 59 Days on average.
| SYRE | WSM | |
|---|---|---|
Market Cap | $7.35B | $28.26B |
Volume | 1,624,631 | 1,108,410 |
Sector | Health | Consumer Cyclical |
52-Week High | $108.92 | $251.81 |
52-Week Low | $22.18 | $168.64 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $6.35B | $28.76B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Williams-Sonoma (WSM) trades at $239.98, up 0.47% today, reflecting strong momentum near its consensus price target of $246.31. The stock shows bullish technical signals with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.10 versus $2.08 expected. Fundamentals are robust with a net income margin of 14.73% and ROE of 54.96%, supported by strategic initiatives like new store openings and collaborations.
The outlook remains positive with raised full-year guidance and market share gains in a flat industry, though risks include housing market sensitivity and high valuation multiples. Analyst consensus leans Hold (57.15%) with upside potential to the high target of $275, but investor caution is warranted given the stock's premium pricing and economic cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
